Telix Further Strengthens European Distribution Network for Illuccix

Melbourne (Australia) and Liège (Belgium)– 22 April 2022. Telix announces agreements with Avanço and THP for the distribution of Telix’s prostate cancer investigational imaging product for the Portuguese and Austrian, Czech Republic and Slovak Republic markets.

Telix is pleased to announce agreements with Sociedade Avanço, Unipessoal, LDA (Avanço) and THP Medical Products Vertriebs GmbH (THP) for the distribution of Telix’s prostate cancer investigational imaging product Illuccix® (Kit for the preparation of gallium-68 (68Ga) gozetotide (also known as PSMA-11) injection) for the Portuguese and Austrian, Czech Republic and Slovak Republic markets, respectively.

Under the terms of the new agreement in Portugal, Avanço, a specialist distributor of nuclear medicine, radiotherapy technologies and urology biopsy products, will be the exclusive commercial distributor of Illuccix in the Portuguese market for a period of three years from the national approval date.

In Austria, the Czech Republic and the Slovak Republic, this new agreement builds on the support THP, a specialist distributor of nuclear medicine products, has provided Telix in distributing 68Ga-PSMA-11 for magisterial use since December 2015. Under the terms of the new agreement, THP will be the exclusive commercial distributor of Illuccix in Austria for a period of five years from national approval.

The signing of these agreements coincides with a recent update to the European Association of Urology (EAU) ‘Guidelines on Prostate Cancer’, which demonstrates an increasing recognition of the clinical utility of prostate specific membrane antigen (PSMA) positron emission tomography (PET) imaging modalities (PSMA PET), including gallium-68 PSMA-11, in the diagnosis of prostate cancer.

Telix CEO EMEA, Richard Valeix added, “Telix is building an extensive distribution network across Europe, with high quality partners with a strong reputation and radiopharmaceutical experience. We are pleased to welcome Avanço and further reinforce our strong collaboration with THP for the Portuguese and Austrian, Czech Republic and Slovak Republic markets, respectively, as we prepare for the European launch of Illuccix. These are important markets for Telix and, with PSMA-PET imaging emerging as a standard of care having recently been included in latest European and U.S. clinical practice guidelines, we look forward to bringing this product to men in need, upon receipt of regulatory approval.

Telix now has European commercial distribution agreements in place in France (IRE ELiT), Germany (Eckert & Ziegler Strahlen- und Medizintechnik AG), Italy (Radius R.r.l), Spain (NUCLIBER S.A.), and the UK and Ireland (Xiel Limited), (all EU5 countries), plus Austria, Slovak Republic and Czech Republic (THP), Greece and Cyprus (BIOKOSMOS S.A.), Poland (Synektik Pharma Sp. Zo. o), Portugal (Avanço), Sweden, Denmark, Finland and Norway (all S Ahlén Medical Nordic AB).

To read the full media release please click here.

To return to Telix’s home page please click here.